FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 305:1599-1605 December 31, 1981 Number 27 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To study the effects of exogenous estrogens on the postmenopausal endometrium, and to determine the time course and minimum dosage of added progestins necessary to oppose estrogen stimulation, we obtained endometrial specimens from symptomatic postmenopausal women being treated with various preparations of estrogens and progestins. Morphologic changes were assessed with light and electron microscopy, and biochemical effects through measurement of DNA synthesis, estradiol and progesterone receptors, and isocitric and estradiol dehydrogenase activity. For comparison, identical studies were carried out on specimens from premenopausal women in the proliferative and secretory phases of their cycle. All the estrogens exerted stimulatory effects in the postmenopausal specimens that were comparable to those observed in the premenopausal proliferative-phase specimens. Estropipate, subcutaneous estradiol, and conjugated estrogens had some hyperphysiologic effects. Maximal progestational effects occurred in the postmenopausal specimens only after norethindrone was administered for six days, and a constant level of activity equal to that in premenopausal secretory-phase specimens was then observed until the 10th day of exposure. Similar maximal effects occurred after six days of treatment with D/L-norgestrel (150 and 5 mg daily [10 mg daily produced less complete changes]). We conclude that many estrogen preparations subject the endometrium to a potent stimulus. Norethindrone and norgestrel are protective because they counteract the proliferative effects of estrogens, but the currently recommended daily dosages of these progestins can be greatly reduced without loss of response.

This article has been cited by other articles:

• Linet, M. S. (2008). Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond. Am J Epidemiol 167: 1416-1420 [Abstract] [Full Text]  
• Schulkin, J. (2008). Hormone Therapy, Dilemmas, Medical Decisions.. J Law Med Ethics 36: 73-88  
• Davis, S R, Dinatale, I, Rivera-Woll, L, Davison, S (2005). Postmenopausal hormone therapy: from monkey glands to transdermal patches. J Endocrinol 185: 207-222 [Abstract] [Full Text]  
• Archer, D. F (2002). Continuous combined hormone replacement therapy and endometrial hyperplasia. BMJ 325: 231-232 [Full Text]  
• Casper, R. F., MacLusky, N. J., Vanin, C., Brown, T. J. (1996). Rationale for Estrogen With Interrupted Progestin as a New Low-Dose Hormonal Replacement Therapy. Reproductive Sciences 3: 225-234 [Abstract]  
• Belchetz, P. E. (1994). Hormonal Treatment of Postmenopausal Women. NEJM 330: 1062-1071 [Full Text]